Reboxetine

Evidence Level: L5

Predicted Indications: 7

Reboxetine

Pharmacist Assessment Report

Reboxetine: Benign paroxysmal torticollis of infancy (top-ranked); see the note below on other candidates (benign paroxysmal torticollis of infancy)

One-Sentence Summary

Reboxetine is a selective norepinephrine reuptake inhibitor, originally used to treat depression (unipolar, endogenous and major depressive disorder) and anxiety disorder. The TxGNN model’s top-ranked prediction is benign paroxysmal torticollis of infancy, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting it. Among the other predictions, agoraphobia and dysthymic disorder have the most plausible support from the literature (Evidence Level L3).

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Benign paroxysmal torticollis of infancy (top-ranked); see the note below on other candidates (benign paroxysmal torticollis of infancy)
TxGNN Prediction Score	0.9992
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Note on the other candidates: The top-ranked prediction has no supporting evidence. Two lower-ranked predictions are better supported and are worth a closer look:

Candidate	TxGNN Score	Evidence Level	Recommendation
Agoraphobia	0.9991	L5	Research Question

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available in the data compiled for this report. Based on known pharmacology, reboxetine is a selective norepinephrine reuptake inhibitor (the pharmacology data show it acts on the norepinephrine transporter, NET, encoded by SLC6A2). Its efficacy in depression is the basis of its original indications, and it may be mechanistically applicable to conditions in which noradrenergic dysregulation plays a role.

Top-ranked prediction (benign paroxysmal torticollis of infancy): The high score is a computational result only. No known mechanistic link exists between norepinephrine reuptake inhibition and this paediatric episodic movement disorder, which is associated with CACNA1A channelopathy and the migraine spectrum. Reboxetine is also not established for use in infants. This prediction should not be pursued without new supporting evidence.

Agoraphobia: Noradrenergic dysregulation is implicated in panic and anxiety disorders, and agoraphobia is commonly comorbid with panic disorder. Reboxetine has shown activity in panic disorder in a small placebo-controlled study and an open-label study of treatment-refractory patients. Agoraphobia-specific outcomes are not reported separately.

Dysthymic disorder: Dysthymia is a chronic depressive disorder closely related to the approved depression indications, so noradrenergic reuptake inhibition is plausible. Dysthymia-specific efficacy data for reboxetine are limited.

Melancholia and neurotic depression: These are depression subtypes or legacy terms within the existing indication space, so they are closer to on-label extensions than true repurposing.

Other predictions (Ohdo syndrome and variants, Ohdo-type blepharophimosis intellectual disability syndrome, Keppen-Lubinsky syndrome, ligneous conjunctivitis, neurotic disorder): These are prediction only, with no evidence found. The rare genetic conditions have no plausible link to norepinephrine reuptake inhibition.

Clinical Trial Evidence

Currently no related clinical trials registered (for the top-ranked prediction or for any of the ten predicted indications).

Literature Evidence

No literature was found for the top-ranked prediction (benign paroxysmal torticollis of infancy). The most relevant publications for the better-supported candidates are shown below.

Agoraphobia / panic disorder

PMID	Year	Type	Journal	Key Findings
38014714	2023	Network meta-analysis	Cochrane Database Syst Rev	Compares pharmacological treatments for panic disorder in adults; covers agoraphobia only indirectly
11838623	2002	Clinical trial	J Clin Psychiatry	Reboxetine reported as effective and well tolerated in panic disorder
12415550	2002	Open-label study	Hum Psychopharmacol	Reboxetine in panic disorder patients who did not respond to SSRIs
40946318	2026	Systematic review	Psychother Psychosom	Treatment options in treatment-resistant anxiety disorders
26635099	2016	Systematic review	Expert Opin Pharmacother	Treatment-resistant panic disorder

Dysthymic disorder

PMID	Year	Type	Journal	Key Findings
21527126	2011	Meta-analysis	J Clin Psychiatry	Antidepressant efficacy in dysthymia versus placebo (not reboxetine-specific)
9818623	1998	Review of clinical trials	J Clin Psychiatry	Reviews reboxetine efficacy and tolerability in major depressive disorder and dysthymia
10628889	1999	RCT (double-blind)	J Affect Disord	Reboxetine versus imipramine in elderly patients with depressive disorders
15358987	2004	Clinical study	J Psychopharmacol	Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in dysthymia (12 patients, single-blind)
10616869	1999	Pilot study	J Geriatr Psychiatry Neurol	Tolerability of reboxetine up to 8 mg/day in 12 elderly patients with major depression or dysthymia

Melancholia / neurotic depression (general depression evidence)

PMID	Year	Type	Journal	Key Findings
29477251	2018	Network meta-analysis	Lancet	Compares 21 antidepressants in MDD; reboxetine tended to rank lower for efficacy and acceptability
19185342	2009	Network meta-analysis	Lancet	Compares 12 newer antidepressants in major depression
20940209	2010	Systematic review and meta-analysis	BMJ	Reboxetine versus placebo or SSRIs in acute depression, assessing publication bias
23007832	2012	Review	Clin Ter	Reboxetine in clinical practice; not approved in the US
10901157	2000	Review	Acta Psychiatr Scand Suppl	Tolerability and safety profile of reboxetine in major depression

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 14474T	Edronax	Tablet 4 mg (as mesilate)	Not available in the data compiled for this report

Safety Considerations

Drug Interactions: The data compiled for this report include only a pharmacology-based target entry (reboxetine acting on the norepinephrine transporter, NET). No clinically graded drug-drug interactions were identified.
Supporting literature notes: One review reports no significant cardiovascular effects, a low potential for drug interactions and no increase in suicidal ideation in reboxetine-treated patients (PMID 10901157). A 2010 BMJ meta-analysis raised concerns about publication bias in reboxetine trials (PMID 20940209).

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as this information was not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (benign paroxysmal torticollis of infancy) rests on a model score alone, with no trials, no literature and no plausible mechanism, and reboxetine is not established in infants. Agoraphobia and dysthymic disorder have modest supporting evidence (L3) but are better treated as research questions than as candidates for clinical adoption.

To proceed, the following is needed:

Mechanism of action data (e.g. from DrugBank) to support mechanistic analysis
The TGA Product Information, to obtain approved indications, warnings and contraindications (a blocking gap for safety screening)
For agoraphobia: controlled studies reporting agoraphobia-specific outcomes
For dysthymic disorder: reboxetine-specific randomised evidence in dysthymia
Registered clinical trials (none found for any candidate) in Australia (ANZCTR) or elsewhere
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.